Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 3Genitourinary 2Breast 2Thoracic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1

Conditions

Prostatic Neoplasms 2

Interventions

Magnetic Resonance Spectroscopy 54Specimen Handling 48aldesleukin 35Docetaxel 30Biopsy 28Bevacizumab 24Gemcitabine 21Cyclophosphamide 21Cisplatin 21Radiotherapy 19Prednisone 17Sorafenib 16Carboplatin 16sargramostim 15PROSTVAC 15Paclitaxel 14Interferon-alpha 14Sunitinib 13ixabepilone 12cabozantinib 12Immunoglobulin G 12Goserelin 12Disulfides 12fludarabine phosphate 11fludarabine 11Nivolumab 11Fluorouracil 11Chemotherapy, Adjuvant 11pembrolizumab 10bicalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Fenretinide × Genitourinary × Clear all
NCT00080899 2015-03-06

Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 3 charts
Genitourinary

Prostatic Neoplasms

NCT00077402 2013-05-15

Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
50 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡